Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Search
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
Biologic Medicines & Biosimilars PDF
bipartnering_letter_bios_1_2.pdf
Pradaxa® (dabigatran etexilate) Overview Factsheet | BI US
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Venu Thatikonda
An in-depth look into working life at Boehringer Ingelheim with Venu Thatikonda.
Partnering Days
Partnering Days
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Cancer
Cancer
FAQ
FAQ
Sites Around the World
Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
Patient Week 2024 demonstrates importance of #PatientPoweredProgress
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Contact Us
Contact Us
Cardiovascular Disease in T2D
Helping pets after a natural disaster in the Carolinas
Helping pets after a natural disaster in the Carolinas
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US
Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.